{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:05:22Z","timestamp":1789103122938,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.10.018","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T22:01:26Z","timestamp":1636408886000},"page":"7166-7174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEVTM) in 1-15\u00a0years-old healthy hepatitis A vaccine-na\u00efve children"],"prefix":"10.1016","volume":"39","author":[{"given":"Subhash","family":"Thuluva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Matur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"TSA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subba Reddy","family":"GV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.10.018_b0005","first-page":"2162","article-title":"Hepatitis A","volume":"73","author":"Brundage","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2021.10.018_b0010","first-page":"38","article-title":"Hepatitis A vaccines: WHO position paper","volume":"75","author":"World Health Organization","year":"2000","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.018_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000252779","article-title":"Hepatitis A: clinical manifestations and management","volume":"53","author":"Jeong","year":"2010","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2021.10.018_b0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.4269\/ajtmh.18-0232","article-title":"Epidemiology of hepatitis A and hepatitis E based on laboratory surveillance data-India, 2014\u20132017","volume":"99","author":"Murhekar","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.10.018_b0025","first-page":"1027","article-title":"Hepatitis A","volume":"86","author":"Matheny","year":"2012","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vaccine.2021.10.018_b0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4254\/wjh.v4.i3.68","article-title":"Hepatitis A: Epidemiology and prevention in developing countries","volume":"4","author":"Franco","year":"2012","journal-title":"World J Hepatol"},{"key":"10.1016\/j.vaccine.2021.10.018_b0035","unstructured":"Global Viral Hepatitis: Millions of People are Affected; 2021. https:\/\/www.cdc.gov\/hepatitis\/global\/index.htm [accessed May 11, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.018_b0040","unstructured":"World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017."},{"key":"10.1016\/j.vaccine.2021.10.018_b0045","unstructured":"Hepatitis A; n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-a [accessed July 1, 2021]."},{"key":"10.1016\/j.vaccine.2021.10.018_b0050","unstructured":"Jacobsen KH. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review. Geneva: WHO; 2009."},{"key":"10.1016\/j.vaccine.2021.10.018_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0974-777X.132040","article-title":"Investigating a community-wide outbreak of hepatitis a in India","volume":"6","author":"Rakesh","year":"2014","journal-title":"J Glob Infect Dis"},{"key":"10.1016\/j.vaccine.2021.10.018_b0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/epirev\/mxj012","article-title":"Hepatitis A in the era of vaccination","volume":"28","author":"Wasley","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"Suppl","key":"10.1016\/j.vaccine.2021.10.018_b0065","first-page":"G94","article-title":"Asian perspectives on viral hepatitis A","volume":"15","author":"Lee","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2021.10.018_b0070","first-page":"699","article-title":"Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries","volume":"128","author":"Mathur","year":"2008","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.018_b0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1440-1746.2006.04232.x","article-title":"Increasing trend of acute hepatitis A in north India: need for identification of high-risk population for vaccination","volume":"21","author":"Hussain","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.018_b0080","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13312-019-1640-1","article-title":"Hepatitis A virus-related pediatric liver disease burden and its significance in the Indian subcontinent","volume":"56","author":"Sood","year":"2019","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.vaccine.2021.10.018_b0085","first-page":"261","article-title":"WHO position paper on hepatitis A vaccines\u2014June 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Weekly Epidemiol Rec"},{"issue":"8","key":"10.1016\/j.vaccine.2021.10.018_b0090","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.4161\/hv.20475","article-title":"Hepatitis A vaccine should receive priority in National Immunization Schedule in India","volume":"8","author":"Verma","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.018_b0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vaccine.2012.04.104","article-title":"Long-term protective effects of hepatitis A vaccines. A systematic review","volume":"31","author":"Ott","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.018_b0100","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1080\/21645515.2016.1197450","article-title":"Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive\u00ae and Havrix\u00ae among children: a 5-year follow-up study","volume":"12","author":"Yu","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.018_b0105","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1080\/21645515.2020.1715687","article-title":"Immunogenicity persistence in children of hepatitis A vaccines Healive\u00ae and Havrix\u00ae: 11 years follow-up and long-term prediction","volume":"16","author":"Wang","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.018_b0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.mjafi.2016.06.011","article-title":"Viral hepatitis: Indian scenario","volume":"72","author":"Satsangi","year":"2016","journal-title":"Med J Armed Forces India"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.018_b0115","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40121-019-00270-9","article-title":"Increasing burden of hepatitis A in adolescents and adults and the need for long-term protection: A review from the Indian subcontinent","volume":"8","author":"Agrawal","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2021.10.018_b0120","unstructured":"National Immunization Schedule (NIS) for Infants, Children and Pregnant Women. https:\/\/main.mohfw.gov.in\/sites\/default\/files\/245453521061489663873.pdf [accessed 18 May 2021]."},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.018_b0125","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4161\/hv.21909","article-title":"Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive\u00ae","volume":"8","author":"Wu","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.018_b0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijid.2007.08.006","article-title":"Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children","volume":"12","author":"Abarca","year":"2008","journal-title":"Int J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:03:47Z","timestamp":1759403027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":26,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21013268"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEVTM) in 1-15\u00a0years-old healthy hepatitis A vaccine-na\u00efve children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}